BEAM - Beam Therapeutics GAAP EPS of -$1.56 misses by $0.26 revenue of $15.79M beats by $8.64M
- Beam Therapeutics press release ( NASDAQ: BEAM ): Q3 GAAP EPS of -$1.56 misses by $0.26 .
- Revenue of $15.79M (+1977.6% Y/Y) beats by $8.64M .
- Cash, cash equivalents and marketable securities were $1.1 billion as of September 30, 2022, as compared to $965.6 million as of December 31, 2021.
For further details see:
Beam Therapeutics GAAP EPS of -$1.56 misses by $0.26, revenue of $15.79M beats by $8.64M